Este estudio tiene como objetivo evaluar cómo un suplemento específico para la salud de la mujer afecta la salud vaginal y la comunidad de microbios en la vagina. Está diseñado para participantes adultas que fueron asignadas como mujeres al nacer y residen en los Estados Unidos. El estudio busca participantes que deseen mejorar su salud vaginal en al menos un 30%. Las personas con ciertas afecciones de salud como enfermedades cardíacas, hepáticas o renales, o aquellas que toman medicamentos que podrían interferir con el estudio, no son elegibles para participar. Esta investigación es importante ya que podría proporcionar información sobre cómo mejorar la salud vaginal, abordando una preocupación común entre muchas mujeres. Los participantes utilizarán el producto del estudio y reportarán sus experiencias de salud electrónicamente durante cinco semanas. Proporcionarán datos autoinformados al inicio, durante y al final del estudio. El estudio se realiza completamente en línea, por lo que no se requieren visitas en persona. Esta configuración permite una evaluación en el mundo real de los efectos del producto sin necesidad de que los participantes viajen o ajusten significativamente sus rutinas diarias. El estudio monitoreará cualquier cambio en los indicadores de salud vaginal para comprender los posibles beneficios de la formulación.
Inclusion Criteria: * Participants must meet all the following criteria: * Adults, assigned female at birth, 21-65 years of age at the time of electronic consent, inclusive of all ethnicities, races * Resides in the United States * Endorses better vaginal health as a primary desire * Has the opportunity for at least 30% improvement in their primary health outcome (i.e., Vaginal Health Survey score ≥ 14 at screening) * Willingness to complete a vaginal biospecimen at 2 timepoints Exclusion Criteria: * Individuals who report any of the following during screening will be excluded from participation: * Report being pregnant, trying to become pregnant, or breastfeeding * Unable to provide a valid US shipping address and mobile phone number ● Reports current enrollment in another clinical trial * Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day) * Unable to read and understand English * Reports a current and/or recent (up to 3 months ago) major illness and/or surgery that poses a known, significant safety risk. * Reports a diagnosis of cardiac dysfunction, liver or kidney disease that presents a known contraindication and/or a significant safety risk with any of the study product ingredients. o NYHA Class III or IV congestive heart failure, atrial fibrillation, uncontrolled arrhythmias, cirrhosis, end-stage liver disease, stage 3b or 4 chronic kidney disease, or kidney failure * Reports taking medications that have a well-established moderate or severe interaction, posing a substantial safety risk with any of the study product ingredients. o Anticoagulants, antihypertensives, anxiolytics, antidepressants, chemotherapy, immunotherapy, sedative hypnotics, seizure medications, medications that warn against grapefruit consumption, corticosteroids at doses greater than 5 mg per day, diabetic medications, oral anti-infectives (antibiotics, antifungals, antivirals) to treat an acute infection, antipsychotics, MAOIs, or thyroid products * Reports current use of the primary ingredient(s) and/or similar product(s) to the active study product(s) that may limit the effects of the study products * Participants must not be undergoing treatment for bacterial vaginosis (ABX) - they will be ineligible if they answer yes to antimicrobials * Participants must not be using prescription or over- the- counter (OTC) treatments for bacterial vaginosis or yeast infections * Participants must not be have been diagnosed with a urinary tract infection (UTI) in the past 3 months * Lack of reliable daily access to the internet
está designado en este estudio
de ser asignado al grupo placebo